Bolt Biotherapeutics Inc (BOLT) Stock Price, Quote & News

Company Profile

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 665 9295

Website: www.boltbio.com

Address:

900 Chesapeake Drive, Redwood City, United States

StewartWatching Jun. 29 at 6:30 PM

Added again at lower levels. F=or me, this is a patience trade. The market can ignore a story for weeks, then suddenly wake up when the catalyst gets closer. $NRED has already shown massive upside potential from its lows before. Now the macro looks even louder: Copper is strategic China is using export controls The U.S. and Japan want secure supply Canada is becoming more important Drilling is still the catalyst I’m watching. High upside! $NRED.CSE $BOLT $METL

0 · Reply

Golibajje Jun. 25 at 6:40 PM

$BOLT i exited too.. sold my last 1700 shares in $4.30S!! They had fireside chat on June 11, heard there was no clarity on what they will do post q3! that was the reason for big dump on June 11! i see couple of key people on linkedin posting ’open to work’.. clean indication they are done!

1 · Reply

Sam1381 Jun. 23 at 2:41 PM

$BOLT Believe your eyes and close your ears! I'm out with this rebound. may come back again if the stock price and its performance is convincing! GL Felas.

0 · Reply

Sam1381 Jun. 22 at 7:18 PM

$BOLT Zack's Rank for BOLT changed from (2)Buy to (4) Sell in the last 2 weeks! What made this shift so quickly ? https://www.zacks.com/stock/quote/BOLT?q=bolt&art_rec=quote-stock_overview-search_filter-zcom-BOLT

0 · Reply

BiotechValues Jun. 22 at 4:30 PM

$BOLT Rodman has a good report out (some excerpts attached below) from May 28th, regarding upcoming key data readout in q3, for the next-gen ISAC BDC-4182 targeting Claudin 18.2 in gastric cancer. At $7M market cap, with $24M cash going into data. So I like R/R if they hit

0 · Reply

Golibajje Jun. 22 at 3:24 PM

$BOLT hedge funds knows the results much earlier than they get released! Pfizer slashed their isac asset recently from its pipeline. So, it look like it won’t work. Also, current mgmt has lawsuit filed in 2021 for manipulating investors on their assets! So, it looks all over with the cash being wiped out from mgmt for their salaries! Bankruptcy next!

0 · Reply

Sam1381 Jun. 22 at 3:05 PM

$BOLT New ATL! Not a good sign. somebody is escaping! I'm still holding my shares! What do u think felas!

0 · Reply

Golibajje Jun. 18 at 9:45 PM

$BOLT 2 mgmt folks salary is more than the market cap of the company! Finding it unbelievable!

0 · Reply

skyrockets_Inc Jun. 18 at 8:31 PM

$BOLT For those follow, as promised last month (re-posted below), I re-ran the numbers today. Looks like I was correct on the dwindle as it's down 15% since my post. Burning 7m a quarter w/ 20m end of March puts them at approx 13m equity as of today or 6.77/share. If there is no news on trial update in the next 4-6 weeks then I expect this to continue to dwindle likely approaching half book value or low 3/share range. I'll consider adding then as I don't believe news is coming tomorrow. They said Q3 data but I don't personally think it will be at the beginning of Q3. I actually trimmed down some of my original position to play some other tickers and will re-evaluate and hopefully re-add more back later if all works out. GLTA!

0 · Reply

Golibajje Jun. 17 at 3:08 PM

$BOLT End is near! Bankruptcy after the results next month!

1 · Reply

Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project

2026-05-28T20:58:57.000Z - 5 weeks ago

Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw

May 12, 2026, 4:05 PM EDT - 7 weeks ago

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Bolt Biotherapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Bolt Biotherapeutics Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Bolt Biotherapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Bolt Biotherapeutics Proxy statement: Proxy filing

2026-03-12T20:31:03.000Z - 4 months ago

Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52)

Mar 12, 2026, 4:05 PM EDT - 4 months ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Bolt Biotherapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Bolt Biotherapeutics Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 4 months ago

Bolt Biotherapeutics to Participate in Upcoming March Conferences

2025-11-12T21:50:29.000Z - 8 months ago

Bolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)

Nov 12, 2025, 4:05 PM EST - 8 months ago

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:00 AM EST - 8 months ago

Bolt Biotherapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Bolt Biotherapeutics Quarterly report: Q3 2025

2025-10-20T10:25:50.000Z - 9 months ago

Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright

2025-10-01T20:10:39.000Z - 9 months ago

Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study

Oct 1, 2025, 4:05 PM EDT - 9 months ago

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

2025-08-15T12:50:22.000Z - 11 months ago

Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split

2025-08-14T20:15:29.000Z - 11 months ago

Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)

Aug 14, 2025, 4:05 PM EDT - 11 months ago

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Bolt Biotherapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Bolt Biotherapeutics Quarterly report: Q2 2025

2025-06-06T23:50:07.000Z - 1 year ago

Bolt Biotherapeutics Inc trading halted, news pending

2025-05-20T12:45:48.000Z - 1 year ago

Bolt Biotherapeutics initiated with a Buy at Lake Street

GMAB

2025-05-13T11:16:52.000Z - 1 year ago

Bolt Biotherapeutics price target lowered to $1 from $1.25 at Stifel

May 12, 2025, 5:30 PM EDT - 1 year ago

Bolt Biotherapeutics Transcript: Status Update

2025-05-12T20:31:39.000Z - 1 year ago

Bolt Biotherapeutics reports Q1 EPS (29c), consensus (36c)

May 12, 2025, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:00 PM EDT - 1 year ago

Bolt Biotherapeutics Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Bolt Biotherapeutics Quarterly report: Q1 2025

2025-05-08T16:25:17.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

HRTX IBRX MDXG QURE SLGL SPRC SRPT

2025-05-08T12:30:14.000Z - 1 year ago

Bolt Biotherapeutics to host KOL call on BDC-3042 Phase 1 results

May 8, 2025, 8:00 AM EDT - 1 year ago

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

2025-04-30T20:50:38.000Z - 1 year ago

Bolt Biotherapeutics announces results for Boltbody ISACs at AACR meeting

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Bolt Biotherapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Bolt Biotherapeutics Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Bolt Biotherapeutics Proxy statement: Proxy Filing

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

2025-03-25T19:19:39.000Z - 1 year ago

Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)

2025-03-25T19:02:15.000Z - 1 year ago

Bolt Biotherapeutics price target lowered to $1.25 from $1.50 at Stifel

Mar 24, 2025, 5:00 PM EDT - 1 year ago

Bolt Biotherapeutics Earnings release: Q4 2024

Mar 24, 2025, 5:00 PM EDT - 1 year ago

Bolt Biotherapeutics Annual report: Q4 2024

Mar 24, 2025, 4:20 PM EDT - 1 year ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

2025-02-11T21:45:40.000Z - 1 year ago

Bolt Biotherapeutics provides update on co-development collaboration with Toray

Feb 11, 2025, 4:05 PM EST - 1 year ago

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

2024-11-12T21:40:03.000Z - 1 year ago

Bolt Biotherapeutics reports Q3 EPS (40c), consensus (35c)

Nov 12, 2024, 4:00 PM EST - 1 year ago

Bolt Biotherapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Bolt Biotherapeutics Quarterly report: Q3 2024

2024-11-07T15:10:49.000Z - 1 year ago

Bolt Biotherapeutics presents updated preclinical data for BDC-4182

Nov 7, 2024, 10:00 AM EST - 1 year ago

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Bolt Biotherapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Bolt Biotherapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Announces Changes to its Board of Directors

Aug 13, 2024, 4:05 PM EDT - 2 years ago

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Bolt Biotherapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Bolt Biotherapeutics Earnings release: Q2 2024

Jul 26, 2024, 10:00 AM EDT - 2 years ago

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

Jul 25, 2024, 10:00 AM EDT - 2 years ago

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Jul 3, 2024, 4:47 PM EDT - 2 years ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Jun 24, 2024, 3:36 PM EDT - 2 years ago

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

StewartWatching Jun. 29 at 6:30 PM

0 · Reply

Golibajje Jun. 25 at 6:40 PM

1 · Reply

Sam1381 Jun. 23 at 2:41 PM

$BOLT Believe your eyes and close your ears! I'm out with this rebound. may come back again if the stock price and its performance is convincing! GL Felas.

0 · Reply

Sam1381 Jun. 22 at 7:18 PM

0 · Reply

BiotechValues Jun. 22 at 4:30 PM

0 · Reply

Golibajje Jun. 22 at 3:24 PM

0 · Reply

Sam1381 Jun. 22 at 3:05 PM

$BOLT New ATL! Not a good sign. somebody is escaping! I'm still holding my shares! What do u think felas!

0 · Reply

Golibajje Jun. 18 at 9:45 PM

$BOLT 2 mgmt folks salary is more than the market cap of the company! Finding it unbelievable!

0 · Reply

skyrockets_Inc Jun. 18 at 8:31 PM

0 · Reply

Golibajje Jun. 17 at 3:08 PM

$BOLT End is near! Bankruptcy after the results next month!

1 · Reply

Golibajje Jun. 12 at 5:56 PM

$BOLT Watch the volume and outflow since yesterday, clearly, someone knows the outcome of those results. Also, they couldn’t able to license the other assets on the pipeline which they were trying from so long! I personally want ISAC approach and results to succeed.. unfortunately, it’s with the wrong mgmt! William and other directors raked up over $15M per year in terms of compensation since 2021 ipo! I trimmed my position to 1700 shares (because I like the isac approach) while I swapped my position to $PASG which is a better bet for acquisition!

0 · Reply

skyrockets_Inc Jun. 11 at 6:51 PM

$BOLT Added 5k shares today. Q3 is swiftly approaching. I plan on emailing CEO in next few days to see if I can get any updates.

0 · Reply

Golibajje Jun. 11 at 6:27 PM

$BOLT Appears to be funds selling prior to ph 1/2 results next quarter! Not looking good considering outflow! Over 84k volume today!

0 · Reply

DARKP00L May. 29 at 12:52 PM

$BOLT 08:33 on May. 29 2026 Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22 #tradeideas

0 · Reply

MilsLearning May. 22 at 7:52 PM

$BOLT 🩳🔥🖕

0 · Reply

MilsLearning May. 22 at 9:27 AM

$BOLT

0 · Reply

Golibajje May. 18 at 3:48 PM

$BOLT Massive asks today! Wondering any news leaks! Regardless, would be adding at eod!

2 · Reply

skyrockets_Inc May. 13 at 7:08 PM

$BOLT Seems they are all in for BDC-3142 which won't post results until 3Q. I expect the stock to dwindle until then (or additional unexpected news). 10Q out yesterday shows net stockholder equity of 20m or ~$10/share so current PPS is still a good value for now. I'll add more to my current position next month after seeing where this stabilizes.

2 · Reply

Golibajje May. 8 at 2:17 PM

$FCHL Saw this in one of the trader group list as a short recommendation.. missed! Worth considering $BOLT which has major clinical trial results in Q3. Could be 500%+ gains there if the results are positive.. it’s the only in that ISAC space.. no competition!

1 · Reply

BillionerOfKing May. 4 at 8:33 PM

$BOLT Current Stock Price: $4.99

0 · Reply

BuyNow_SellLater Apr. 27 at 4:57 PM

$BOLT good day to add here

0 · Reply

SheriffGrover Apr. 25 at 10:30 PM

$BOLT https://www.fiercebiotech.com/biotech/pfizer-ends-work-phase-1-stage-immunostimulatory-drug-conjugate-cancer-patients Thoughts ? TIA

0 · Reply

Market Cap	7.78M
Revenue (ttm)	7.70M
Net Income (ttm)	-33.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-433.51%
Debt to Equity Ratio	0.00

Volume	4,400
Avg Vol	31,356
Day's Range	N/A - N/A
Shares Out	1.92M
Stochastic %K	45%
Beta	1.16
Analysts	Sell
Price Target	$6.00